CELESTINE TUNG to Predictive Value of Tests
This is a "connection" page, showing publications CELESTINE TUNG has written about Predictive Value of Tests.
Connection Strength
0.024
-
Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017 10; 147(1):41-46.
Score: 0.024
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.